Teva cinqair status 2025 or 2026?

Could you clarify what you mean by “status” for Teva Cinqair (reslizumab) in 2025 or 2026? Are you asking about regulatory approval, market availability, dosing/usage guidelines, safety warnings, or something else (pricing, patents, competition)?

Here is a quick, general status as context:
- Cinqair is the brand name for reslizumab, an anti-IL-5 monoclonal antibody used as add-on maintenance therapy for adults with severe eosinophilic asthma.
- FDA approval: reslizumab was approved in 2016 for adults with severe eosinophilic asthma.
- Dosing: typically 3 mg/kg given IV every 4 weeks.
- Safety: there is a boxed warning for anaphylaxis and other serious hypersensitivity reactions after IV infusion; contraindicated in patients with a history of anaphylaxis to reslizumab or its components.
- Use: approved for adults; not for pediatric use; not for acute asthma relief.
- Market status: in many regions it remains an available biologic option, but like all biologics, its place in therapy depends on region, payer coverage, and competing IL-5/anti-IL-5R agents (e.g., mepolizumab, benralizumab) and dupilumab.

If you want, I can look up the latest regulatory and market status for 2025/2026 for your region (FDA, EMA, or other authorities). Tell me which country or region you’re interested in, and whether you want regulatory approvals, prescribing guidelines, or pricing/coverage details.